Vector Science & Therapeutics Corp. (TSXV: PAIN) has announced the appointment of Dexter Fowler as Chief Athletic Officer for Valor, its sports medicine division. Fowler, a 14-year Major League Baseball veteran and 2016 World Series Champion, will lead athlete engagement and onboarding across professional sports.
Fowler's Distinguished Career
Fowler spent 14 seasons as a center fielder and leadoff hitter for the Colorado Rockies, Houston Astros, Chicago Cubs, St. Louis Cardinals, and Los Angeles Angels. He is best known for leading off Game 7 of the 2016 World Series with a home run that sparked the Cubs' first championship in 108 years. After retiring, he founded 400 Ventures, an athlete and entertainment management firm, and holds ownership stakes in AFC Bournemouth and Lorient FC.
Addressing Soft Tissue Injuries
Valor's approach targets the anatomical ecosystem—tendons, ligaments, fascia, and surrounding vasculature—using peptide-based molecular instruction delivered transdermally. This aims to support repair and resilience at the tissue level, addressing the cumulative burden from repetitive mechanical loading that often leads to career-ending injuries.
Statements from Leadership
Dexter Fowler stated: "Professional sports is repetitive stress at full intensity, every day. The same swing, the same sprint, the same throw…until the soft tissue that makes it possible breaks down faster than it can recover. That’s not an injury. That’s the job. Athletes deserve better options. That’s why I’m here."
Darryl Drake Jr., President of Valor, added: "Soft tissue injuries that end careers rarely arrive without warning. They accumulate. Dexter has lived that. His voice opens doors no clinical argument alone can."
About Valor
Valor is the sports medicine division of Vector Science & Therapeutics Corp., built to bring clinically sound transdermal peptide delivery to elite athletes and sports medicine professionals. Its approach targets tissue repair, accelerated recovery, and site-directed pain mitigation, leveraging Vector's pharmaceutical-grade peptide portfolio and cGMP manufacturing capabilities in Mequon, Wisconsin.
